Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: antibacterials - Pylum Biosciences

Drug Profile

Research programme: antibacterials - Pylum Biosciences

Alternative Names: Acinetobacter infection therapy - Pylum Biosciences; Avidocin therapeutics; Avidocin™ proteins; Clostridium difficile infection therapy - Pylum Biosciences; Escherichia coli infection therapy - Pylum Biosciences; Pseudomonas aeruginosa infection therapy - Pylum Biosciences; Yersinia pestis therapy - Pylum Biosciences

Latest Information Update: 29 Jan 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AvidBiotics Corp.
  • Class Bacteriocins; Proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Clostridium infections
  • Research Acinetobacter infections; Escherichia coli infections; Prevotella infections; Pseudomonal infections
  • No development reported Shiga-toxigenic Escherichia coli infections; Yersinia infections

Most Recent Events

  • 29 Jan 2018 Early research in Prevotella infections in USA (unspecified route) (AvidBiotics pipeline, January 2018)
  • 07 Nov 2017 Antibacterials are still in early research in Acinetobacter-infections, Escherichia coli infections, Gram-negative infections and Pseudomonal infections in USA (AvidBiotics Pipeline, November 2017)
  • 07 Nov 2017 Antibacterials are still in preclinical development for Clostridium difficile infections in USA (Avidbiotics pipeline, November 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top